AIBORN receives investment from Medical Data Vision in a capital and business alliance for its medical-records AI

AIBORN receives investment from Medical Data Vision in a capital and business alliance for its medical-records AI

1 October 2026: AIBORN, a Tokyo company that develops AI tools for medical records, announced on 1 October 2026 that it has received an investment from Medical Data Vision (MDV) and entered a capital and business alliance with it. MDV holds one of the largest clinical databases in Japan. AIBORN did not state the amount.

Not yet independently verified. Single source: the company's own release. It states no amount and no stage; this is a strategic investment within a business alliance rather than a priced funding round. We will update this when it can be confirmed, and remove this note.

The round

According to AIBORN's release on PR TIMES, the investment comes from Medical Data Vision as part of a capital and business alliance. No amount, stage or other investors are given, so this should be read as a strategic investment rather than a priced venture round. The release says the two companies will work more closely on product development, on supplying AIBORN's tools to medical institutions, and on support after installation. MDV has resold AIBORN's product since August 2025.

What the company does

AIBORN, founded in February 2025, makes Katanashi, a medical-records AI tool. It transcribes consultations and conferences and turns them into draft notes in a structured clinical format for doctors and nurses to review, so clinicians spend less time typing records. The alliance with MDV gives it access to an established sales channel into Japanese hospitals and clinics.

Why it matters for buyers

Japan's hospitals face a shortage of doctors and nurses and rules that limit doctors' overtime, which makes documentation time a pressing cost. AI scribes are spreading quickly, and alliances with established health-data companies are one way small vendors reach hospitals. For buyers, the alliance also raises a data question: how a tool connected to a large clinical-data company handles patient information.

What to check

• Where audio and transcripts are processed and stored, and whether any data is shared with the investor.
• Accuracy for your specialties and terminology, and how clinicians correct drafts.
• Integration with your electronic medical record system.
• Compliance with Japan's personal information and medical information guidelines.
• Support arrangements after installation, which the alliance is meant to strengthen.

Company profile on TrustList: AIBORN

Related on TrustList:

• Henry raises 1.2 billion yen from regional banks for hospital software
• Parakeet Health raises a $10 million Series A led by Canvas Ventures for patient-access AI
• Prodoc AI raises seed funding led by the Dr A. Velumani Family Office for an AI layer for hospitals

Sources

• AIBORN via PR TIMES: AIBORN、メディカル・データ・ビジョンからの出資を受け資本業務提携 - 1 October 2026